Savara wins European and Australian patents for Molbreevi through 2041

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. COF
6. SMCI
7. GOOGL
8. RTX
9. TSLA
10. UAL

Go back to Savara wins European and Australian patents for Molbreevi through 2041

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

July 30, 2026 8:05 AM EDT

-- In December 2025, Savara and PARI Were Granted a Joint European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI, Delivered Via PARIs Proprietary eFlow® Nebulizer System, Through March 2043 --

LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the European Patent Office (EPO)... More